Advanced Biomed Inc. (ADVB) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2025. Advanced Biomed Inc. is a Nevada-based holding company operating primarily through subsidiaries in Taiwan and China. The company focuses on the research and development of microfluidic biochip technologies for precision oncology detection and treatment. As of the reporting date, the company has no revenue-generating products and is in the pre-commercialization stage, awaiting regulatory approvals for its product candidates.
Key Financial Metrics
| Metric | Q1 2026 (Ended Sept 30, 2025) | Q1 2025 (Ended Sept 30, 2024) |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(386,901) | $(265,580) |
| Operating Expenses | $(523,914) | $(520,027) |
| Cash and Cash Equivalents | $2,656,519 | $2,646,992 |
| Working Capital | $2,799,181 | $3,143,443 |
| Net Cash Used in Operating Activities | $(610,342) | $(29,680) |
| Net Cash Provided by Financing Activities | $447,462 | $392,525 |
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased by approximately 46% to $386,901 from $265,580 in the prior year quarter. This was driven by a 30% increase in Research and Development (R&D) expenses to $235,992, offset partially by a 15% decrease in General and Administrative (G&A) expenses to $287,922.
- Other Income Decline: Total other income decreased by 46% to $137,013 from $254,447, primarily due to a reduction in foreign exchange gains.
- Cash Flow Deterioration: Net cash used in operating activities increased significantly to $610,342 from $29,680, reflecting higher operating outflows and changes in working capital (specifically a decrease in accounts payable).
- Related Party Liabilities: Amounts due to related parties (major stockholders and related corporations) increased, with current liabilities rising to $1,485,078 and non-current liabilities to $190,959.
Outlook, Risks, and Management Commentary
- Going Concern: The company has disclosed substantial doubt about its ability to continue as a going concern due to recurring losses and negative cash flows. Management plans to sustain operations through additional capital raises, cash from operations (once products are approved), and financial support from related parties.
- Product Pipeline: The company expects to begin clinical research for its lung cancer screening kit (A+LCGuard) in January 2026, with completion anticipated by June 2026. Regulatory approval is expected by October 2027. No revenue is expected until regulatory approvals are obtained.
- Financing: The company completed an IPO in March 2025 raising approximately $5.49 million in net proceeds. Additionally, an Equity Line of Credit (ELOC) agreement was entered into in June 2025, allowing for the sale of up to $25 million of common stock.
- Risks: Key risks include the inability to secure additional financing, delays in regulatory approvals, foreign currency fluctuations (NTD, CNY, HKD vs. USD), and the company's reliance on related party loans.
Investor Verification Checklist
- Cash Runway: Verify if the current cash balance of ~$2.66 million is sufficient to fund operations through the planned clinical trials in 2026 without immediate dilution.
- Related Party Dependence: Review the terms of the significant loans from major stockholders and related corporations (totaling over $1.6 million) to assess repayment obligations and potential conversion to equity.
- Regulatory Timeline: Confirm the status of the A+LCGuard clinical trial protocol and the likelihood of meeting the January 2026 start date.
- Going Concern Status: Monitor subsequent filings for any new financing agreements or waivers of debt from related parties.
- Foreign Exchange Exposure: Assess the impact of currency fluctuations on the company's financial statements, given operations in Taiwan and China.